Medical Devices - San Francisco, California, United States
We're developing the first single touchpoint implant solution to automate diabetes management using advanced control algorithms. Diabetes management is notoriously burdensome and complex, yet abnormal insulin delivery routes and flawed technologies limit diabetics' ability to achieve tightly controlled glucose levels - crucial to preventing long-term complications (kidney/heart disease, new blindness) but also near-term consequences (as serious as death). Our solution will be a paradigm shift in how diabetes is managed by utilizing the superior kinetics of the intraperitoneal (IP) cavity and delivering insulin physiologically just as a healthy pancreas would.